I agree that this site is using cookies. You can find further informations here.
X
Wach, Małgorzata
65  results:
Search for persons X
?
1

The Outcomes of Ponatinib Therapy in Patients With Chronic ..:

Sacha, Tomasz ; Szczepanek, Elżbieta ; Dumnicka, Paulina...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  6 - p. 405-415 , 2022
Link: https://doi.org/10.1016/..
 
?
2

Acalabrutinib Versus Investigator's Choice in Relapsed/Refr..:

Ghia, Paolo ; Pluta, Andrzej ; Wach, Małgorzata...
HemaSphere.  6 (2022)  12 - p. e801 , 2022
Link: https://doi.org/10.1097/..
 
?
3

CLL-091: Acalabrutinib Versus Idelalisib Plus Rituximab (Id..:

Ghia, Paolo ; Pluta, Andrzej ; Wach, Malgorzata...
Clinical Lymphoma Myeloma and Leukemia.  20 (2020)  - p. S220-S221 , 2020
Link: https://doi.org/10.1016/..
 
?
4

Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamu..:

Ghia, Paolo ; Pluta, Andrzej ; Wach, Malgorzata...
Clinical Lymphoma Myeloma and Leukemia.  19 (2019)  - p. S280-S281 , 2019
Link: https://doi.org/10.1016/..
 
?
5

Idelalisib addition has neutral to beneficial effects on qu..:

Montillo, Marco ; Illés, Árpád ; Robak, Tadeusz...
Health and Quality of Life Outcomes.  17 (2019)  1 - p. , 2019
Link: https://doi.org/10.1186/..
 
?
6

Advances in hematology – research that revolutionized patie..:

Wach, Małgorzata ; Podhorecka, Monika ; Cioch, Maria...
Polish Journal of Public Health.  125 (2015)  1 - p. 32-35 , 2015
Link: https://doi.org/10.1515/..
 
?
7

Different prognosis of acute myeloid leukemia harboring mon..:

Wawrzyniak, Ewa ; Wierzbowska, Agnieszka ; Kotkowska, Aleksandra...
Leukemia Research.  37 (2013)  3 - p. 293-299 , 2013
Link: https://doi.org/10.1016/..
 
?
8

Neutropenic enterocolitis: a serious complication during th..:

Wach, Malgorzata ; Dmoszynska, Anna ; Wasik-Szczepanek, Ewa...
Annals of Hematology.  83 (2003)  8 - p. , 2003
Link: https://doi.org/10.1007/..
 
?
9

Intravascular B-cell lymphoma in a 38-year-old woman: a cas..:

Wach, Małgorzata ; Dmoszyńska, Anna ; Skomra, Danuta..
Annals of Hematology.  80 (2001)  4 - p. 224-227 , 2001
Link: https://doi.org/10.1007/..
 
?
10

Idelalisib addition has neutral to beneficial effects on qu..:

Montillo, Marco ; Illés, Árpad ; Robak, Tadeusz...
10.1186/s12955-019-1232-8.  , 2023
Link: https://hdl.handle.net/2..
 
?
11

Acalabrutinib Versus Investigator's Choice in Relapsed/Refr..:

Ghia, Paolo ; Pluta, Andrzej ; Wach, Malgorzata...
HemaSphere. -6 : 12 (2022), p. 1-10. -Hemasphere. - 2572-9241.  , 2022
Link: https://hdl.handle.net/2..
 
?
12

Acalabrutinib Versus Investigator's Choice in Relapsed/Refr..:

Ghia, Paolo ; Pluta, Andrzej ; Wach, Małgorzata...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666115/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
13

Idelalisib addition has neutral to beneficial effects on qu..:

Montillo, Marco ; Illés, Árpad ; Robak, Tadeusz...
info:eu-repo/semantics/altIdentifier/doi/10.1186/s12955-019-1232-8.  , 2019
Link: https://hal.univ-lille.f..
 
?
14

Idelalisib addition has neutral to beneficial effects on qu..:

Montillo, Marco ; Illés, Árpád ; Robak, Tadeusz...
Health and Quality of Life Outcomes. -17 : 1 (2019) p. 1-11. -Health Qual. Life Outcomes. - 1477-7525. - 1477-7525.  , 2019
Link: http://hdl.handle.net/24..
 
?
15

Idelalisib addition has neutral to beneficial effects on qu..:

Montillo, Marco ; Illés, Árpad ; Robak, Tadeusz...
info:eu-repo/semantics/altIdentifier/doi/10.1186/s12955-019-1232-8.  , 2019
Link: https://hal.univ-lille.f..
 
1-15